160 results
424B3
BLRX
Bioline Rx Ltd
2 Aug 12
Prospectus supplement
12:00am
tax consequences relating to the ownership or disposition of our ordinary shares or ADSs, both referred to below as the Shares, or our warrants. You … should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under
424B2
BLRX
Bioline Rx Ltd
13 Jun 14
Prospectus for primary offering
12:00am
financial performance.
The PPACA also requires the medical device industry to subsidize healthcare reform in the form of a 2.3% excise tax on U.S. sales … investment company, or PFIC, for U.S. federal income tax purposes in 2014 or in any subsequent year. There may be negative tax consequences for U.S
424B5
BLRX
Bioline Rx Ltd
5 Mar 15
Prospectus supplement for primary offering
12:00am
reform in the form of a 2.3% excise tax on U.S. sales of certain medical devices beginning January 1, 2013 and also includes new regulatory mandates … investment company, or PFIC, for U.S. federal income tax purposes in 2015 or in any subsequent year. There may be negative tax consequences for U.S
424B5
qarz49o 59avo1p13yuo
3 Mar 14
Prospectus supplement for primary offering
12:00am
F-3
4ji2w9
30 May 14
Shelf registration (foreign)
12:00am
F-1
EX-10.18
kdj0d4v750
24 Sep 10
Registration statement (foreign)
12:00am
F-3/A
ffb38f2ce0 jb
23 Jul 12
Shelf registration (foreign) (amended)
12:00am
424B5
2ff 5yxj7w
17 May 13
Prospectus supplement for primary offering
12:00am
POS AM
f4jbwmv
25 Jul 12
Prospectus update (post-effective amendment)
12:00am
20-F
r438p6ql67 tet
22 Mar 12
Annual report (foreign)
12:00am
424B5
5j67dx
17 May 13
Prospectus supplement for primary offering
12:00am
20FR12B
EX-4.1
x1fyjb0i3ts 1cmpfy72
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
424B5
ifjq2jcp4 qp
6 Mar 15
Prospectus supplement for primary offering
12:00am
424B5
iqxaym8n6 c9
4 Mar 14
Prospectus supplement for primary offering
12:00am